Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during […]